OptiBiotix Health PLC Director/PDMR Shareholding (1109G)
25 Mars 2022 - 3:36PM
UK Regulatory
TIDMOPTI
RNS Number : 1109G
OptiBiotix Health PLC
25 March 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company ")
PDMR Dealings
OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d
eveloping compou n ds to tackle obesity, high cholesterol, blood
pressure and diabetes, ann o un ces that it was notified today of
the following share purchases made by René Kamminga, CEO of
Optibiotix Ltd:
Date of transaction Number of shares purchased Price
23 March 2022 10,000 40p
--------------------------- ------
24 March 2022 2,656 38p
--------------------------- ------
Following the above transactions, Mr Kamminga is interested in
55,844 ordinary shares in the Company, representing 0.06 per cent.
of the Company's issued share capital.
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
the UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
--------------------------------------------------------------------------------------------
a. Name René Kamminga
--------------------------------------- ---------------------------------------------------
2 Reason for notification
--------------------------------------- ---------------------------------------------------
a. Position/Status PDMR
--------------------------------------- ---------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
--------------------------------------- ---------------------------------------------------
b. LEI 213800UKYQFT941QHS14
--------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------------------------
a. Description of Ordinary shares of 2p each
the financial
instrument, type
of instrument
ISIN: GB00BP0RTP38
Identification
Code
--------------------------------------- ---------------------------------------------------
b. Nature of the Purchase of 12,656 ordinary shares in the
transaction Company
--------------------------------------- ---------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
--------------------------------------- ---------------------
40p 10,000
38p 2,656
--------------------- ----------------
d. Aggregated information
* Volume 12,656
Average price of 39.6p
* Price
--------------------------------------- ---------------------------------------------------
e. Date of the transaction 23 and 24s March 2022
--------------------------------------- ---------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
--------------------------------------- ---------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSELFLIEESEDD
(END) Dow Jones Newswires
March 25, 2022 10:36 ET (14:36 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
